MarginsXMarginsX
Home › Data Desk › Private placement (PIPE)

Private placement (PIPE)

Automated articles on Private placement (PIPE), built every day from SEC filings, prices and our own datasets.

All topics · Dilution · Offerings · Convertible notes · FDA approval · Licensing and milestone payments · At-the-market offering · Delistings · Mergers and acquisitions · Restaurants · Casinos · Foreign private issuer · Material weakness · Early-stage clinical trials · Oncology · FDA setbacks · Reverse split · Private placement (PIPE) · Warrants and inducements · Biofuels and renewable natural gas · Insider buying · Debt financing · Divestitures · Solar · Artificial intelligence · Equity line of credit · Late-stage clinical trials · Daily feature · Going-concern doubt · Week ahead · Customer concentration · Late filings · Weekly roundups · Rates and the dollar · Banking · Quarterly results · Dual-class shares · Inflation and interest rates · Share buybacks · AI data centers · Executive turnover · GPUs and accelerators · Big movers · IPO · Public offerings · SPAC · China exposure · Convertible preferred stock · Natural gas and LNG · Cryptocurrency · Bankruptcy · Tobacco and vaping · Related-party loans · Nasdaq deficiency notice · Payments and fintech · Alcoholic beverages · Oil and gas production · Delisting · Aerospace and aviation · Tariffs · Medical devices · 13G holders · Carbon and clean energy credits · Semiconductors · Cannabis · Electric vehicles · Name or ticker change · Aesthetics and dermatology · Pet products · Stablecoins · Critical minerals · Gold mining · Mineral exploration · Auditor changes · Drones · Cell and gene therapy · Defense and military · Exchange listing notices · OTC quotation · Battery energy storage · Authorized share increase · 13D stakes · Robotics · Market wrap · Dividend payments · Spin-offs · Carbon capture · Impairment charges · Firearms and ammunition · Reverse merger · Securities class actions · Generative AI · Layoffs and restructuring · Asset management and BDCs · Hydrogen and fuel cells · Joint ventures · REITs and real estate · Reverse splits · Data centers · Backlog and contracted revenue · Trucking and logistics · Agriculture · Wind power · Video games and esports · War and geopolitical risk · Insurance carriers · Medicare and Medicaid reimbursement

Super League Enterprise Inc. puts a 424B5 prospectus supplement on file

On Nov 16, 2026, Super League Enterprise Inc. (SLE) filed a 424B5: a prospectus supplement for a sale from its shelf. (SEC EDGAR, 424B5, Nov 16, 2026)

November 16, 2026 · data as of 2026-11-16

Surrozen Inc. files a 424B5 prospectus supplement

Surrozen Inc. (SRZN) filed a 424B5 on Nov 16, 2026, a prospectus supplement for a sale from its shelf. (SEC EDGAR, 424B5, Nov 16, 2026)

November 16, 2026 · data as of 2026-11-16

Private placement (PIPE) this week: filings, movers and insider trades to Nov 13, 2026

We track 479 companies in our small-cap universe whose filings center on private placement (PIPE). (MarginsX topic index of company filings, Nov 13, 2026)

November 14, 2026 · data as of 2026-11-14

Cartesian Growth Corporation IV's 10-Q carries going-concern doubt

In its 10-Q, filed Nov 13, 2026, Cartesian Growth Corporation IV (CGCF) disclosed substantial doubt that it can carry on as a going concern. (SEC EDGAR, 10-Q, Nov 13, 2026)

November 14, 2026 · data as of 2026-11-13

Adage Capital Management, L.P. passes 5.0% of First Tracks Biotherapeutics Inc.

In a Schedule 13G filed Nov 12, 2026, Adage Capital Management, L.P. reported 2.1 million shares of First Tracks Biotherapeutics Inc. (TRAX) as of Sep 30, 2026, 5.8% of the class. (SEC EDGAR, SCHEDULE 13G, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Alaunos Therapeutics Inc. puts an S-3 shelf registration on file

On Nov 13, 2026, Alaunos Therapeutics Inc. (TCRT) filed an S-3: a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 13, 2026)

November 14, 2026 · data as of 2026-11-13

ABVC BioPharma Inc. files a 424B4 prospectus supplement

ABVC BioPharma Inc. (ABVC) filed a 424B4 on Nov 13, 2026, a final prospectus with the offering's price. (SEC EDGAR, 424B4, Nov 13, 2026)

November 14, 2026 · data as of 2026-11-13

Lyell Immunopharma Inc. puts an S-3 shelf registration on file

On Nov 13, 2026, Lyell Immunopharma Inc. (LYEL) filed an S-3: a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 13, 2026)

November 14, 2026 · data as of 2026-11-13

Hurst Jonathan discloses a 5.2% stake in Agility Robotics Inc.

Hurst Jonathan filed a Schedule 13D on Nov 12, 2026, reporting 12.7 million shares of Agility Robotics Inc. (AGLT), 5.2% of the class, as of Nov 4, 2026. (SEC EDGAR, SCHEDULE 13D, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Evommune Inc. revenue down 100.0% in the quarter to Sep 30, 2026

The 10-Q that Evommune Inc. (EVMN) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Lucid Group Inc. has about 2.7 months of cash at its recent burn

The 10-Q that Lucid Group Inc. (LCID) filed on Nov 9, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 9, 2026)

November 14, 2026 · data as of 2026-11-09

Gossamer Bio Inc. revenue rises 189.1% in the quarter to Sep 30, 2026

Gossamer Bio Inc. (GOSS) filed its 10-Q on Nov 10, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

November 14, 2026 · data as of 2026-11-10

Azora Therapeutics Inc. adds 444.1% to its share count in one report

The 10-Q that Azora Therapeutics Inc. (AZR) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Reed's Inc. adds 146.9% to its share count in one report

The 10-Q that Reed's Inc. (REED) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Follow topics in MarginsX